casi cast
Bill Speltz: Don't blame the Montana defense for Saturday's Brawl debacle in BozemanCINCINNATI (AP) — The Cincinnati Bengals took care of business and won three straight games for the first time this season. Cincinnati is playing its best football, but it might be too late to sneak into the playoffs, with five teams battling for the two remaining AFC postseason spots. At 7-8, the Bengals are on the bubble along with two other teams that have the same record, the Colts and Dolphins. To have a chance, the Bengals will need to beat the visiting Denver Broncos (9-6) on Saturday, then try to take down the Steelers (10-5) at Pittsburgh in the regular-season finale. They'll need some help from other teams, too. The rub for the Bengals is that they have yet to beat a team with a winning record this season. Now with some momentum for the first time, the Bengals will have to clear that hurdle. “It’s just what it’s supposed to feel like for us. This is our expectation," coach Zac Taylor said after the Bengals beat the Cleveland Browns 24-6 on Sunday. “We just put ourselves in a position to now play some real meaningful games. ... We found a way to get the win and now we can turn our focus to a short week and the Denver Broncos.” Joe Burrow became the first player in NFL history to throw for at least 250 yards and three or more touchdowns in seven consecutive games. One of his TD passes, to Tee Higgins, came as he was falling down. He finished 23 for 30 for 252 yards. ... Ja'Marr Chase continues to build his resume as he strives to win the receiving “triple crown.” He had six catches for 97 yards and a touchdown against the Browns and leads the league in receptions, yards and TDs. ... K Cade York tied a franchise record with a 59-yard field goal. “The guys have responded this way all season,” Taylor said. “We lost some heartbreakers to be quite frank, and games that just came down to the end. It doesn’t mean that we’ve had a bad football team and we weren’t in it. We’ve been in this, and now — I don’t want to say getting our confidence back, because we’ve had confidence — but we’re just making the plays necessary at the critical points of the game to take control of these games. That’s really what’s happened the last three weeks, and we’ve got to continue that.” Burrow has fumbled 10 times this season. Against the Browns, he lost a fumble on a strip-sack with the Bengals on the Cleveland 2-yard-line. Last week, S Jordan Battle scooped a fumble and ran it all the way back, only to fumble as he crossed the goal line, leading to a touchback. Against the Browns, he intercepted a second-half pass from Dorian Thompson-Robinson in the end zone. The Bengals' defense has nine takeaways in the past two games. Cincinnati's depleted offensive line allowed four sacks. The offensive line took a hit when tackle Amarius Mims went out with an ankle injury and didn't return. 5.1 — Yards per carry by RB Chase Brown, who seems to get better every week. He had 18 carries for 91 yards. The Bengals continue their improbable effort to slip into the playoffs when they host the Broncos in their home finale on Saturday. They finish the season the following week at Pittsburgh. AP NFL: https://apnews.com/hub/NFL
Edinburgh Airport shut down by IT issue just as holiday travel season gets under wayBenchmark reissued their buy rating on shares of i3 Verticals ( NASDAQ:IIIV – Free Report ) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $33.00 price target on the stock. Several other analysts also recently issued reports on the stock. BMO Capital Markets cut their target price on shares of i3 Verticals from $23.00 to $21.00 and set a “market perform” rating on the stock in a research note on Thursday, October 3rd. Stephens reissued an “overweight” rating and set a $29.00 target price on shares of i3 Verticals in a research note on Friday, August 16th. Raymond James lowered their price target on shares of i3 Verticals from $31.00 to $28.00 and set a “strong-buy” rating on the stock in a report on Monday, August 12th. KeyCorp lowered their price target on shares of i3 Verticals from $28.00 to $27.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. Finally, DA Davidson restated a “buy” rating and set a $32.00 price target on shares of i3 Verticals in a report on Monday, September 30th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $27.14. View Our Latest Analysis on i3 Verticals i3 Verticals Price Performance Institutional Investors Weigh In On i3 Verticals A number of large investors have recently bought and sold shares of IIIV. Comerica Bank boosted its holdings in i3 Verticals by 46.0% in the first quarter. Comerica Bank now owns 2,133 shares of the company’s stock worth $49,000 after purchasing an additional 672 shares in the last quarter. Quantbot Technologies LP bought a new stake in i3 Verticals in the third quarter worth $109,000. SG Americas Securities LLC bought a new stake in i3 Verticals in the second quarter worth $116,000. Atom Investors LP bought a new stake in i3 Verticals in the third quarter worth $218,000. Finally, Sanctuary Advisors LLC bought a new stake in i3 Verticals in the second quarter worth $292,000. 84.22% of the stock is currently owned by institutional investors. About i3 Verticals ( Get Free Report ) i3 Verticals, Inc provides integrated payment and software solutions primarily to the public sector and healthcare markets in the United States. It operates in two segments, Software and Services, and Merchant Services. The company offers payment processing services that enables upper and lower court case management, collections, finance and accounting, motor vehicle and carrier registration, e-filing and taxation, license plate inventory, property tax management, utility billing, professional licensing, document workflow, and law enforcement software; assists public schools in completing payment processing functions, including accepting payments for online or at school lunches, and school activities. Read More Receive News & Ratings for i3 Verticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for i3 Verticals and related companies with MarketBeat.com's FREE daily email newsletter .Safeguard yourself from Bird Flu amid global concerns
US agencies should use advanced technology to identify mysterious drones, Schumer says
As anticipation builds for ‘ Captain America: Brave New World ’, Anthony Mackie offers fans a glimpse of what to expect from the upcoming film. Taking up the mantle of Captain America as Sam Wilson, Mackie has reassured audiences that the film will stay true to the grounded, espionage-driven tone. It will follow the theme of its previous films like ‘ Captain America: The Winter Soldier ’. With its focus on realistic storytelling and character depth, the film aims to set itself apart from Marvel’s recent forays into cosmic and fantastical adventures. Anthony Mackie On How ‘Captain America’ Films Keep The Audience Invested Anthony Mackie confirmed that ‘Captain America: Brave New World ’ will have a grounded approach to storytelling. Mackie shared that despite the inclusion of characters like Red Hulk , fans can expect a narrative that feels rooted in reality. “ If you look at these Marvel movies, they go with different genres, ” Mackie explained at the Disney APAC Content Showcase (via Deadline ). “ You have the fantasy world, you have the space world, you have the raccoon world. The Captain America stories, it has always been the realistic, grounding world. This movie stays in line with the original Captain America, of that thrill, of that espionage, of that grounded nature with storytelling and really investing the actual audience into the story .” Mackie also reflected on how his character, Sam Wilson, steps into the mantle of Captain America in a way that reflects his unique identity. “ It’s very different with the serum — you can fight anybody. When you don’t have the serum, you have to be smart and engineer different ways of defeating enemies, ” Mackie stated. He believes that while Sam knows all about leadership like Steve Rogers, he lacks that Super Soldier Serum, which makes it a lot more realistic. The actor also discussed how Sam Wilson is carving out a unique legacy as Captain America. Anthony Mackie Teases A Brand New Overpowered Captain America Suit The Captain America actor also teased the advancements in Sam Wilson’s suit, revealing that it’s a game-changer for his abilities. He credited the suit and its upgraded qualities to Wakandan technology. “ It’s a high-tech suit...I can kick harder, I can fly faster, and it gives me the ability to be more agile,” he said, adding that it pushes his skills to a “completely different level .” This integration of Wakandan technology promises an exciting evolution for Wilson as he fully embraces his role as the new Captain America. The actor also revealed that his favorite superhero of all time was the Incredible Hulk . However, he also jokingly stated that he was always confused about Hulk’s pants staying on while he transformed. “How come everything came off except the pants?’ Everything, his shirt, his shoes, came off, but his pants stayed ,” the actor joked. Moreover, fans can look forward to a thrilling continuation of the Captain America story when the film debuts on February 14, 2025. This article first appeared on FirstCuriosity and was syndicated with permission.
ASX set to rise, Wall Street wavers as tech giants slump
US agencies should use advanced technology to identify mysterious drones, Schumer saysInsider Selling: Service Co. International (NYSE:SCI) VP Sells 56,100 Shares of Stock
Riding a 3-game win streak, the Bengals cling to playoff hopes with the Broncos nextOhio State runs over Indiana 38-15It was called a ‘cheat bot’. Now, this uni is paying for students to use it
( MENAFN - GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Peripheral T Cell Lymphomas pipeline constitutes 40+ key companies continuously working towards developing 40+ Peripheral T Cell Lymphomas treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Peripheral T Cell Lymphomas Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. “Peripheral T Cell Lymphomas Pipeline Insight, 2024 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral T Cell Lymphomas Market. Some of the key takeaways from the Peripheral T Cell Lymphomas Pipeline Report: Companies across the globe are diligently working toward developing novel Peripheral T Cell Lymphomas treatment therapies with a considerable amount of success over the years. Peripheral T Cell Lymphomas companies working in the treatment market are HUYA Bioscience International, Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others , are developing therapies for the Peripheral T Cell Lymphomas treatment Emerging Peripheral T Cell Lymphomas therapies in the different phases of clinical trials are- HBI-8000, AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others are expected to have a significant impact on the Peripheral T Cell Lymphomas market in the coming years. In December 2024, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced new data showcasing significant improvements in quality of life for patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. The findings were presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California. In December 2024, Secura Bio, Inc. (Secura Bio), an integrated pharmaceutical company focused on the global development and commercialization of effective oncology therapies, presented two posters at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, CA. The first poster showcased new data from the Company's Phase 2 PRIMO trial of duvelisib for treating relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL), while the second poster outlined the clinical design for the planned Phase 3 randomized trial of duvelisib in R/R nodal T-follicular helper cell lymphoma (TERZO). Peripheral T Cell Lymphomas Overview Peripheral T-cell lymphomas (PTCL) are a diverse group of aggressive blood cancers that develop in T-cells, a type of white blood cell involved in immune function. Unlike other types of lymphoma, PTCL originates outside the bone marrow, typically in lymph nodes, spleen, or other tissues. Symptoms may include swollen lymph nodes, fever, weight loss, night sweats, and skin rashes. PTCL is rare and often more difficult to treat compared to other lymphomas. Treatment options may include chemotherapy, immunotherapy, stem cell transplants, and targeted therapies, depending on the specific subtype and stage of the disease. Get a Free Sample PDF Report to know more about Peripheral T Cell Lymphomas Pipeline Therapeutic Assessment- Emerging Peripheral T Cell Lymphomas Drugs Under Different Phases of Clinical Development Include: HBI-8000: HUYA Bioscience International AT-104: Applied Therapeutics Auto 5: Autolus AK 104: Akeso Biopharma Tolinapant: Astex Pharmaceuticals Duvelisib: Secura Bio Lacutamab: Innate Pharma AZD 4205: Dizal Pharmaceutical Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology Peripheral T Cell Lymphomas Route of Administration Peripheral T Cell Lymphomas pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Subcutaneous Intravenous Oral Intramuscular Intra-tumoral Molecule Type Peripheral T Cell Lymphomas Molecule Type Peripheral T Cell Lymphomas Products have been categorized under various Molecule types, such as Monoclonal antibodies Immunoglobulins Small molecules Pyrimidines Proteins and Peptides Product Type Peripheral T Cell Lymphomas Pipeline Therapeutics Assessment Peripheral T Cell Lymphomas Assessment by Product Type Peripheral T Cell Lymphomas By Stage and Product Type Peripheral T Cell Lymphomas Assessment by Route of Administration Peripheral T Cell Lymphomas By Stage and Route of Administration Peripheral T Cell Lymphomas Assessment by Molecule Type Peripheral T Cell Lymphomas by Stage and Molecule Type DelveInsight's Peripheral T Cell Lymphomas Report covers around 40+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Peripheral T Cell Lymphomas product details are provided in the report. Download the Peripheral T Cell Lymphomas pipeline report to learn more about the emerging Peripheral T Cell Lymphomas therapies Some of the key companies in the Peripheral T Cell Lymphomas Therapeutics Market include: Key companies developing therapies for Peripheral T Cell Lymphomas are - Celleron Therapeutics, Myeloid Therapeutics, Astex Pharmaceuticals, Citius Pharmaceuticals, Innate Pharma, Secura Bio, Genor Biopharma Co., Ltd., CerRx, Inc., Dizal Pharmaceuticals, Kura Oncology, Inc., Viracta Therapeutics, Autolus Therapeutics, Affimed Therapeutics, C4 Therapeutics, Kymera Therapeutics, Daiichi Sankyo, SciTech Development LLC, Sorrento Therapeutics, Bristol-Myers Squibb, Shanghai Yingli Pharmaceutical, Ono Pharmaceutical, and others. Peripheral T Cell Lymphomas Pipeline Analysis: The Peripheral T Cell Lymphomas pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral T Cell Lymphomas with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral T Cell Lymphomas Treatment. Peripheral T Cell Lymphomas key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Peripheral T Cell Lymphomas Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral T Cell Lymphomas market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Peripheral T Cell Lymphomas drugs and therapies Peripheral T Cell Lymphomas Pipeline Market Drivers Increase in incidences of PTCL, rising investment for the development of advanced technologies, surge in government initiatives to promote research and awareness about the disease are some of the important factors that are fueling the Peripheral T Cell Lymphomas Market. Peripheral T Cell Lymphomas Pipeline Market Barriers However, high cost associated with the treatment, lack of skilled professionals for early diagnosis of the disease and other factors are creating obstacles in the Peripheral T Cell Lymphomas Market growth. Scope of Peripheral T Cell Lymphomas Pipeline Drug Insight Coverage: Global Key Peripheral T Cell Lymphomas Companies: HUYA Bioscience International, Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others Key Peripheral T Cell Lymphomas Therapies: HBI-8000, AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others Peripheral T Cell Lymphomas Therapeutic Assessment: Peripheral T Cell Lymphomas current marketed and Peripheral T Cell Lymphomas emerging therapies Peripheral T Cell Lymphomas Market Dynamics: Peripheral T Cell Lymphomas market drivers and Peripheral T Cell Lymphomas market barriers Request for Sample PDF Report for Peripheral T Cell Lymphomas Pipeline Assessment and clinical trials Table of Contents 1. Peripheral T Cell Lymphomas Report Introduction 2. Peripheral T Cell Lymphomas Executive Summary 3. Peripheral T Cell Lymphomas Overview 4. Peripheral T Cell Lymphomas- Analytical Perspective In-depth Commercial Assessment 5. Peripheral T Cell Lymphomas Pipeline Therapeutics 6. Peripheral T Cell Lymphomas Late Stage Products (Phase II/III) 7. Peripheral T Cell Lymphomas Mid Stage Products (Phase II) 8. Peripheral T Cell Lymphomas Early Stage Products (Phase I) 9. Peripheral T Cell Lymphomas Preclinical Stage Products 10. Peripheral T Cell Lymphomas Therapeutics Assessment 11. Peripheral T Cell Lymphomas Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Peripheral T Cell Lymphomas Key Companies 14. Peripheral T Cell Lymphomas Key Products 15. Peripheral T Cell Lymphomas Unmet Needs 16 . Peripheral T Cell Lymphomas Market Drivers and Barriers 17. Peripheral T Cell Lymphomas Future Perspectives and Conclusion 18. Peripheral T Cell Lymphomas Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. MENAFN23122024003238003268ID1109025437 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.Viper Energy stock soars to all-time high of $56.08